[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@d_stock07734 "$NWBO ESMO 2025 preview Merck hopes for Daiichi redemption Did Merck strike the deal with Daiichi after Merck replaced BMS as the sponsor for the SPORE project Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition Conclusions This study reveals that timing may impact how ATL-DC and aPD1 combined therapies can alter the immune landscape of GBM and highlights tumor-associated macrophages as a major obstacle to clinical benefit"
X Link @d_stock07734 2025-10-17T21:13Z XXX followers, XXX engagements

"@mazzulo_lorie @andrewcaravello BPs would not take hectic working hours to complete the manufacturing facilities if they were not something concerning their future. Merck never chose the same type of hectic working hours to solve BCG shortage issue"
X Link @d_stock07734 2025-10-16T05:09Z XXX followers, XXX engagements

"$NWBO $RVMD is going to face competition from Incyte. INCB161734 (KRAS G12D) Preliminary Phase X Results Of INCB161734 A Novel Oral KRAS G12D Inhibitor In Patients With Advanced Or Metastatic Solid Tumors (Session Title: Proffered paper session: Developmental therapeutics. October XX 8:45 10:20 a.m. ET 2:45 4:20 p.m. CEST. Abstract #916O.)"
X Link @d_stock07734 2025-10-17T21:04Z XXX followers, 2020 engagements

"What would happen to the sp if Merck could front $NWBO over at least $10b for collaborations on combining its over XX new growth drivers with DCVax What would happen to the sp if Baker Brothers could make a big investment in $NWBO Amgen acquired Horizon $28b in cash and its Actimmune cannot bring big revenue unless it can be combined with the Direct. All the combinations Dr. Bosch showed in the presentation had 'I' which most likely stands for Interferon Gamma-1b (ACTIMMUNE)"
X Link @d_stock07734 2025-10-11T15:59Z XXX followers, 3612 engagements

"@Michael48826289 If I am not mistaken TIGIT inhibitor is among XX new growth drivers that Merck repeatedly claim to have blockbuster potentials"
X Link @d_stock07734 2025-10-16T20:53Z XXX followers, XXX engagements

"@mazzulo_lorie @andrewcaravello Did you see how Merck set up and acquired Immune Design I was wondering if Merck was trying to do the same on $NWBO. But Merck didn't make it"
X Link @d_stock07734 2025-10-16T05:11Z XXX followers, XXX engagements

"$NWBO It's interesting that Roche sponsored a trial on using the combination of XCR1 with DC vaccine and Atezolizumab (PD-L1 inhibitor) to treat late stage small cell lung cancer. Among XX patients enrolled XX% are PD-L1 negative. The results were presented one year ago. There will be a presentation on this trial next week. Long term survivors from Phase Ib-II trial of tumor-loaded monocyte-derived dendritic cell vaccination plus atezolizumab in ES-SCLC Not sure if the research institution at Spain is involved in the symphony. But it's good to see Roche has interest in DC vaccine therapy."
X Link @d_stock07734 2025-10-16T20:46Z XXX followers, 3637 engagements

"@mazzulo_lorie @andrewcaravello Why would he leave for Regeneron as an associate director on field medical affairs Why did Roger Perlmutter take the CEO job of a startup one week after stepping down from Merck Did Merck place most of its $40b strategic investment after Perlmutter left"
X Link @d_stock07734 2025-10-15T22:01Z XXX followers, XXX engagements

"A collaboration trial between Merck and TILT Biotherapeutics on ovarian cancer. One of the conclusions is that Median progression-free survival and overall survival were XX and XXX days respectively. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (PROTA) The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial"
X Link @d_stock07734 2025-10-13T05:17Z XXX followers, XXX engagements

"$NWBO Going through the products from some BPs and wondering if those products can be combined with DCVax to treat cancer is really a wonderful experience. ACTIMMUNE (interferon gamma-1b): No need to explain this one. Aimovig (erenumab-aooe) is a CGRP inhiibtor: The inhibition of CGRP may lead to an increase in the DC's antigen-presenting capacity potentially boosting T-cell activation. By blocking CGRP's suppressive effects CGRP inhibitors can allow for greater DC activation and higher production of pro-inflammatory cytokines like TNF- which CGRP normally represses. Blocking CGRP's influence"
X Link @d_stock07734 2025-10-16T15:29Z XXX followers, 3231 engagements

"@bullishbruk Do you know what is TLR4 TLR4 can boost the production of TNFa and IL-12 p70 to strengthen anti-tumor immune response. $NWBO 10Q mentioned about TLR agonist. Most likely it could be TLR4. Now do your homework and find out which company owns TLR4"
X Link @d_stock07734 2025-10-16T00:32Z XXX followers, XXX engagements

"$NWBO BeOne Medicines Sonrotoclax (BCL2 inhibitor) Granted Breakthrough Therapy Designation by U.S. FDA BCL-2 inhibitorsenhance the anti-cancer immune response by improving dendritic cell (DC) function not just by killing cancer cells.By inhibiting BCL-2 these drugs boost DCs' ability to present antigens to T cells which activates them to fight tumors.This dual action can be particularly effective when combined with other immunotherapies likePD-1 inhibitorsas it synergizes to improve anti-tumor immunity. Getting more bang for their buck: BCL2 inhibitors boost dendritic-cell function to"
X Link @d_stock07734 2025-10-14T05:17Z XXX followers, 1023 engagements